Patras University Hospital
Rio, Achaia, 26504, Greece
NCT Number: NCT03319472
Pleural effusions (PE) are common conditions that signal either infection or cancer. The investigators aim to develop, validate, and prospectively assess the MAPED score, a clinical score that predicts malignancy at admission. This tool will assist clinicians all over the world to rapidly assess the probability of an effusion being malignant within 4 hours of admission.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Rio, Achaia, 26504, Greece
Background: Pleural effusions (PE) are common conditions that signal either pleural-disseminated infection or cancer. While these diagnoses bear tremendous importance for patients, they require invasive procurement of pleural tissues and/or cells and time. Simple and rapid diagnostic markers of pleural malignancy at admission that streamline diagnostic and treatment efforts remain unidentified.
Objective: To develop, validate, and prospectively assess markers of malignancy of PE at admission.
Methods: A prospective cohort of patients with PE from different etiologies will be recruited stating on 11.21.2013 and prospectively ending on 11.21.2023. Data will be collected within 4 hours of admission including history, chest X-ray, and blood and pleural fluid (PF) cell counts and basic biochemistry. Pleural fluid and serum will be biobanked for future analyses. Patients will sign informed consent forms. Diagnosis will be confirmed using standard microbiology, cytology, histology, and imaging techniques. Patients undiagnosed within a month will be excluded. Variables will be entered into binary regression and receiver-operator analyses using malignancy as the target to develop the MAPED score, a clinical score that predicts malignancy at admission. MAPED will be retrospectively validated in separate published cohorts from the first therapeutic interventions in malignant effusion (TIME) 1-3 trials from Oxford UK. Data will be censored and analyzed three times, at 40-month intervals since study initiation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: One month post-admission
Cytologic or histologic evidence of malignant cells or tissues in the pleural space.
University of Patras
Other
Clinical Identification of Malignant Pleural Effusions in the Emergency Department
Acronym: MAPED
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02500277
Actinomycetales Infections, Bacterial Infections
Chandigarh, India
View Trial DetailsNCT00896285
Malignant Pleural Effusion, Neoplasms
Sacramento, California, United States
View Trial DetailsNCT06892691
Cancer, Neoplasms
New York, United States
View Trial DetailsNCT05797649
Actinomycetales Infections, Bacterial Infections
Hong Kong, New Territories
View Trial Details